VolitionRX Limited (VNRX) Share Price

215,000 shares traded on7/9/2024 at 11;25 @ $0.60. Lately its been 20,000 a day. I think somebody knows something is up. TWT.

VNRX under $2

BEWARE OF THE STOCK PUMPING CRIMINAL WHO SHORTS HIS OWN PUMPS!!!!!!!

CHECK OUT HIS POSTING HISTORY!!!!!!!

VNRX...NEW BIO PLAY UNDERWAY WITH A 1.32 TRIGGER UP A HEAD!!!

VNRX.......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

VNRX.............................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

VNRX......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

VNRX new 52 week low

VNRX................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

HORRENDOUS DUMPING

VNRX new 52 week low

Give me $2.50 !!

$$ VNRX $$

Seems like very bad news stocks getting hammard premarket.

News: $VNRX Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

AUSTIN, Texas , July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today...

In case you are interested VNRX - Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

* * $VNRX Video Chart 07-14-2020 * *

Link to Video - click here to watch the technical chart video

good news today, hope it runs to $5

Whatever happened to the supposed out of the box blood test for a colonoscopy procedure replacement. This company has been a funding animal like a pac-man eating of the $$$$$$$$$'s!
Geez!
rod

I suspect the patent is about more than COVID...


Introduction
Neutrophils are the most abundant leukocytes in mammals and, as a first line of defense against microbes, they play crucial roles in innate immune responses. The homeostasis of neutrophils is maintained by balancing their short lifespan in the circulation with their regulated release from the bone marrow. Neutrophils have various types of granules, containing hundreds of proteins. These include bactericidal proteins, some of them with important effects on innate and adaptive immune responses, such as a-defensins, the cathelicidin human cationic antimicrobial protein of 18 kDa, and lactoferrin, among others. LL-37, a proteolytic product of human cationic antimicrobial protein of 18 kDa, has important chemotactic and immunostimulatory effects, as discussed below (1).

The mechanisms used by neutrophils to eliminate microbes include phagocytosis, generation of reactive oxygen species (ROS), and the release of microbicidal molecules from granules (degranulation). In 2004, another distinct antimicrobial activity was described: neutrophils extrude a meshwork of chromatin fibers that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (Fig. 1), cathepsin G, and myeloperoxidase (MPO) (2). These structures, called neutrophil extracellular traps (NETs), represent an important strategy to immobilize and kill invading microorganisms. The NET scaffold consists of chromatin fibers with a diameter of 15–17 nm; DNA and histones represent the major NET constituents (2). Mass spectrometry has identified various additional proteins associated with NETs, including components from various types of granules. Although conserved proteins are found in extracellular trap fractions, it is still unclear whether the peptide composition of these structures may vary depending on the specific stimulus that promotes NET formation (3, 4).

Cont..


https://www.jimmunol.org/content/189/6/2689.long

4/23/20 - Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.

Full PR:
https://finance.yahoo.com/news/volition-files-patent-nu-q-123000672.html

Volition Video Gallery:

https://volition.com/press-room/video-gallery

More eavesdropping:



gordoncamelion wrote on 20.05.20 11:13:27 Entry No. 1.763 (63,747,802) The results from the large lung cancer study should come in Q2 2020. Here are the topics that will come this year. Upcoming Milestones We expect the company to accomplish some of the near-term milestones below: ? Q2 Clinical performance data from individual assays and in the panel combinations across the range of cancers ? Q2 / 3 Clinical data from COVID-19 studies currently underway ? Advance large-scale colorectal and lung cancer trials in Europe, Asia and the US ? Determine the level of tumor associated nucleosomes using mass spectrometry and identify NEW biomarker targets ? Q2 Utilize Nu.Q sequencing to identify tumor of origin and specific mutations ? Q3 Utilize in conjunction with Nu.Q immunoassay approach to enhance performance ? Q4 Launch Nu. Q Vet




https://www.wallstreet-online.de/diskussion/1275261-1761-1770/bluttest-krebserkennung-valitionrx-was

Eavesdropping:


Labsolute wrote on 21.05.20 17:25:37 Entry No. 1.785 (63.763.840) Reply to entry no .: 63.763.585 by tycoon111 am 05/21/20 16:55:36 I am optimistic from the bottom up and may be concerned with my investments, maybe that's the reason And: the burn rate is great, nothing is too high !! Capital increases are also absolutely normal for such companies. Volition has never had any problems getting fresh cash in the past and has always been supported by the state. You can not be blamed for burning the shareholders' money senselessly! And slowly what needs to be monetized is your opinion as so I take on young impatient small shareholders. I see the data that was published a week ago and I know that such a diagnosis no other company in the world can - not at Stage1 and not at the price and time required. And in my opinion it will stay that way for a long time! I do not know whether the price climbs up or down as your question was - but I see a ridiculous market capitalization which can only increase tenfold in the short term (vet / Lung china / COVID) with just one successful piece of the puzzle and on the other hand I see a stable balance sheet a lot of cash and competitors who all still need a lot of time! So an excellent change risk ratio, even if small cap very risky!





Labsolute wrote on 23.05.20 14:18:01 Entry No. 1.789 (63.779.455) no topic - welcome to high risk - high reward. You have to get along with the Vola - especially difficult as an ETF investor. Always think of fear vs greed and rationally rethink everything in difficult phases. We are in a wild market phase: from V-recovery to deepest depression, everything is in the room - if you have already felt uncomfortable, rethink the position size. Otherwise there is now more than enough cash in the company to survive this phase and we can look forward to further data and news this year. Reynolds directly secured a small package for $ 2.75. Think that calms many people again.



https://www.wallstreet-online.de/diskussion/1275261-1781-1790/bluttest-krebserkennung-valitionrx-was

EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING


HEALTHCAREJUNE 2, 2020 / 4:08 PM / UPDATED 13 HOURS AGO
BRIEF-Eight Corporation Limited Reports 23.8% Stake In Volitionrx Ltd As Of May 29
1 MIN READ

June 2 (Reuters) - VolitionRX Ltd:

* EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING

* EIGHT CORPORATION LTD-ON MAY 29, CONTACTED VOLITIONRX’S BOARD TO REQUEST EXPANSION OF BOARD AS WELL AS APPOINTMENT OF 3 DIRECTORS SELECTED BY THEM

* EIGHT CORPORATION LTD - REQUESTED VOLITIONRX’S BOARD FORM A COMMITTEE TO EVALUATE, AMONG OTHER THINGS, BUSINESS STRATEGY AND SUCCESSION PLANS

* EIGHT CORPORATION LTD - HAD PREVIOUSLY REPORTED 29.2% STAKE IN VOLITIONRX AS OF MAY 7 Source text: (bit.ly/2Y8YnEv) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.




https://uk.reuters.com/article/brief-eight-corporation-limited-reports/brief-eight-corporation-limited-reports-238-stake-in-volitionrx-ltd-as-of-may-29-idUKFWN2DF0O6

Epigenetic change has also compromised our immune systems. I believe this is the primary reason why seniors are dying of COVID in the nursing homes.

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

https://volition.com/press-room/press-releases/volition-announces-cameron-reynolds-president-and-chief-executive-officer-invited-as-presenter-at-maxims-covid-19-virtual-conference

Epigenetics is an issue in much more than cancer.

I suspect that this is just an initial focus for this company but will have to do more research.

Only 8% insty ownership but this bears looking into:


2020-05-07 13D/A Eight Corp Ltd 12,045,332 29.20
2019-08-01 13D Cotterford Co Ltd 12,041,570 29.30
2019-02-25 13G/A Hever Investments Ltd 11,877,476 29.40
2019-02-14 13G/A Lagoda Investment Management, L.P. 1,643,714 4.70
2019-02-11 13D/A Innes Guy Archibald 1,875,701 5.30
2018-11-09 13D/A Faulkes Martin Charles 1,977,284 5.60
2018-11-09 13D/A Reynolds Cameron John 2,562,967 7.20
2017-02-08 13G/A MANCHESTER MANAGEMENT CO LLC 1,212,159 4.60
2016-12-29 13D Hunt David 63,440,000 62.30

Intriguing stock, from the Ibox:


Nucleosomics® Accessing the Epigenome



The company’s NuQ® range of research uses only epigenetic research tools, and is available to life science researchers in a familiar and accessible format – the simple immunoassay.

VNRX this little bull is about to blow up. The cancer play of the year

* * $VNRX Video Chart 09-25-2019 * *

Link to Video - click here to watch the technical chart video

* * $VNRX Video Chart 09-24-2019 * *

Link to Video - click here to watch the technical chart video

VNRX amazing strength!!

VNRX OMG look at her run!!

VNRX here she goes...this monster is going to blow up!!

VNRX boom...a monster!!!

VNRX boom and halt!!! come on baby!!

VNRX boom Out of the gate!

VNRX Daily Chart

96% Technical BUY Rating

https://www.barchart.com/stocks/quotes/VNRX/opinion

VNRX about to become a low float monster. Just wait for the volume to really kick in

VNRX wowza what a close..morning call went out!!

VNRX look at her go..oh my lord!!

VNRX friday monster surge...this one is gonna be fun!!

Here we go...VNRX the next bio beast!!!

VNRX new nasy jazzy bio wonder play...watch this beast take off!!

News: $VNRX Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas , Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.Q TM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin....

Find out more VNRX - Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

Not today tho.. Chuckle

I do like what I'm seeing here

News: $VNRX Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

AUSTIN, Texas , July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.8 million in aggregate amount of shar...

Read the whole news Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

News: $VNRX VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas , July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, B...

In case you are interested VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

Cotterford Co Ltd has filed a new 13G, reporting 29.4% ownership in $VNRX - https://fintel.io/so/us/vnrx and https://fintel.io/i/cotterford